Regenxbio Inc. RGNX) on Thursday reported a loss of $61.9 million in its third quarter.
Shortly after, an explosion occurred the scene, Esposito said at a press conference, injuring seven firefighters, including ...
RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026 Pivotal trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback